New antibody weapon targets Hard-to-Treat blood cancers
NCT ID NCT05822843
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This early-phase study tested a new antibody drug called ESG206 in 13 adults with advanced B-cell blood cancers (like lymphoma or leukemia) that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the best dose. Researchers also looked for signs that the drug could shrink tumors. The study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.